Page 275 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 275
Viral Hepatitis: Hepatitis C - Clinical (New Compounds, Resistance)
P0888 EFFECT OF BASELINE FACTORS ON RESPONSE TO THE
FIXED-DOSE COMBINATION OF DACLATASVIR (DCV),
ASUNAPREVIR (ASV) AND BECLABUVIR (BCV), WITH
OR WITHOUT RIBAVIRIN (RBV), IN PATIENTS WITH HCV
GENOTYPE 1 INFECTION AND CIRRHOSIS
Christophe Hezode*, Robert Herring Jr, Paul J. Pockros, Aasim Sheikh,
John Vierling, Samuel Lee, Alexander Thompson, Rafia Bhore,
Eric A. Hughes, E Scott Swenson, Philip D. Yin, France
P0889 EFFECT OF BASELINE FACTORS ON RESPONSE TO THE
FIXED-DOSE COMBINATION OF DACLATASVIR (DCV),
ASUNAPREVIR (ASV) AND BECLABUVIR (BCV) IN NON-
CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 INFECTION
K. Rajender Reddy*, Kimberly L. Beavers, Stuart Gordon,
Stephen Harrison, Nancy Reau, Joseph Yozviak, Victor DeLedinghen,
Brian Conway, Edmund Tse, Rafia Bhore, Navdeep Boparai,
Eric Hughes, E. Scott Swenson, Philip D. Yin, The United States
P0890 NOVEL CYCLOPHILIN INHIBITOR CPI-431-32 SHOWS
BROAD SPECTRUM ANTIVIRAL ACTIVITY BY BLOCKING
REPLICATION OF HCV, HBV AND HIV-1 VIRUSES ePOSTERS
Philippe Gallay*, Udayan Chatterji, Michael Bobardt, Daren Ure,
Daniel Trepanier, Robert Foster, Cosme Ordonez, The United States
P0891 RESISTANCE ANALYSIS OF VIROLOGIC FAILURES IN
HEPATITIS C GENOTYPE 1 INFECTED PATIENTS TREATED
WITH GRAZOPREVIR/ELBASVIR ± RIBAVIRIN: THE
C-WORTHY STUDY
Stuart Black*, Irene Pak, Paul Ingravallo, Pat McMonagle, Robert Chase,
Melissa Shaughnessy, Peggy Hwang, Barbara Haber, P. Richard Harrigan,
Chanson Brumme, Anita Y. M. Howe, The United States
P0892 IMPACT OF HCV INFECTION IN A HIV COHORT FOLLOWED
OVER 18 YEARS: PAST AND PRESENT
Alvaro Mena*, Iria Rodriguez Osorio, Héctor Meijide,
Ángeles Castro Iglesias, Soledad López calvo, Pilar Vázquez Rodríguez,
Berta Pernas, Marta Grandal, José Domingo Pedreira, Eva Poveda, Spain
Vienna, Austria • April 22–26, 2015 275
P0888 EFFECT OF BASELINE FACTORS ON RESPONSE TO THE
FIXED-DOSE COMBINATION OF DACLATASVIR (DCV),
ASUNAPREVIR (ASV) AND BECLABUVIR (BCV), WITH
OR WITHOUT RIBAVIRIN (RBV), IN PATIENTS WITH HCV
GENOTYPE 1 INFECTION AND CIRRHOSIS
Christophe Hezode*, Robert Herring Jr, Paul J. Pockros, Aasim Sheikh,
John Vierling, Samuel Lee, Alexander Thompson, Rafia Bhore,
Eric A. Hughes, E Scott Swenson, Philip D. Yin, France
P0889 EFFECT OF BASELINE FACTORS ON RESPONSE TO THE
FIXED-DOSE COMBINATION OF DACLATASVIR (DCV),
ASUNAPREVIR (ASV) AND BECLABUVIR (BCV) IN NON-
CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 INFECTION
K. Rajender Reddy*, Kimberly L. Beavers, Stuart Gordon,
Stephen Harrison, Nancy Reau, Joseph Yozviak, Victor DeLedinghen,
Brian Conway, Edmund Tse, Rafia Bhore, Navdeep Boparai,
Eric Hughes, E. Scott Swenson, Philip D. Yin, The United States
P0890 NOVEL CYCLOPHILIN INHIBITOR CPI-431-32 SHOWS
BROAD SPECTRUM ANTIVIRAL ACTIVITY BY BLOCKING
REPLICATION OF HCV, HBV AND HIV-1 VIRUSES ePOSTERS
Philippe Gallay*, Udayan Chatterji, Michael Bobardt, Daren Ure,
Daniel Trepanier, Robert Foster, Cosme Ordonez, The United States
P0891 RESISTANCE ANALYSIS OF VIROLOGIC FAILURES IN
HEPATITIS C GENOTYPE 1 INFECTED PATIENTS TREATED
WITH GRAZOPREVIR/ELBASVIR ± RIBAVIRIN: THE
C-WORTHY STUDY
Stuart Black*, Irene Pak, Paul Ingravallo, Pat McMonagle, Robert Chase,
Melissa Shaughnessy, Peggy Hwang, Barbara Haber, P. Richard Harrigan,
Chanson Brumme, Anita Y. M. Howe, The United States
P0892 IMPACT OF HCV INFECTION IN A HIV COHORT FOLLOWED
OVER 18 YEARS: PAST AND PRESENT
Alvaro Mena*, Iria Rodriguez Osorio, Héctor Meijide,
Ángeles Castro Iglesias, Soledad López calvo, Pilar Vázquez Rodríguez,
Berta Pernas, Marta Grandal, José Domingo Pedreira, Eva Poveda, Spain
Vienna, Austria • April 22–26, 2015 275
